Clinical Trial Update: Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism

View source ↗

Summary

A completed follow-up trial in end-stage renal disease patients treated with Zemplar (paricalcitol) to prevent and treat secondary hyperparathyroidism; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Chronic Kidney Failure, Secondary Hyperparathyroidism | Status: COMPLETED | Results posted: 2012-03-12